Inhibiting SARS‐CoV‐2 infection with lysosomal alkalizers

Understanding the SARS‐CoV‐2 virus’ routes of infection, virus–host–protein interactions, and mechanisms of virus‐induced cytopathic effects will greatly aid in the discovery and design of new therapeutics to treat COVID‐19. Chloroquine and hydroxychloroquine, extensively explored as clinical agents...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:FASEB J
Autori principali: Gorshkov, Kirill, Chen, Catherine, Bostwick, Robert, Rasmussen, Lynn, Tran, Bruce, Cheng, Yu‐Shan, Xu, Miao, Pradhan, Manisha, Henderson, Mark, Zhu, Wei, Oh, Eunkeu, Susumu, Kimihiro, Wolak, Mason, Shamim, Khalida, Huang, Wenwei, Hu, Xin, Shen, Min, Klumpp‐Thomas, Carleen, Itkin, Zina, Shinn, Paul, de la Torre, Juan Carlos, Simeonov, Anton, Michael, Samuel, Hall, Matthew, Lo, Donald, Zheng, Wei
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Federation of American Societies for Experimental Biology 2021
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239884/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fasebj.2021.35.S1.02122
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi